Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. (2021)

First Author: Kolamunnage-Dona R
Attributed to:  EPSRC Centre for New Mathematical Sciences Capabilities for Healthcare Technologies funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2021.05.015

PubMed Identifier: 34052255

Publication URI: http://europepmc.org/abstract/MED/34052255

Type: Journal Article/Review

Volume: 75

Parent Publication: Journal of hepatology

Issue: 4

ISSN: 0168-8278